Cybin (NASDAQ:HELP) Cut to “Strong Sell” at Wall Street Zen

by · The Markets Daily

Wall Street Zen cut shares of Cybin (NASDAQ:HELP – Free Report) from a sell rating to a strong sell rating in a research report report published on Saturday morning,Wall Street Zen reports.

Other equities research analysts have also issued reports about the company. Wells Fargo & Company assumed coverage on Cybin in a research report on Monday, July 27th. They issued an “overweight” rating and a $16.00 price target for the company. Barclays assumed coverage on Cybin in a research note on Friday, September 18th. They set an “overweight” rating and a $35.00 price objective on the stock. Finally, TD Cowen upped their target price on Cybin from $8.00 to $62.00 and gave the company a “buy” rating in a report on Thursday, August 20th. Six analysts have rated the stock with a Buy rating, According to data from MarketBeat.com, the stock presently has an average rating of “Buy” and an average price target of $46.33.

Get Our Latest Analysis on Cybin

Cybin Trading Down 2.4%

HELP opened at $11.42 on Friday. The firm has a market capitalization of $908.46 million, a PE ratio of -3.78 and a beta of 0.53. Cybin has a twelve month low of $3.76 and a twelve month high of $15.15. The firm’s 50-day moving average price is $11.83 and its 200 day moving average price is $7.62.

Cybin (NASDAQ:HELP – Get Free Report) last released its quarterly earnings data on Friday, August 14th. The company reported ($0.91) EPS for the quarter, missing analysts’ consensus estimates of ($0.80) by ($0.11). As a group, analysts predict that Cybin will post -2.95 earnings per share for the current fiscal year.

Insider Activity at Cybin

In related news, CFO Greg Cavers purchased 3,000 shares of Cybin stock in a transaction dated Tuesday, September 29th. The shares were acquired at an average cost of $12.91 per share, with a total value of $38,730.00. Following the purchase, the chief financial officer owned 3,000 shares of the company’s stock, valued at approximately $38,730. The trade was a ∞ increase in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, insider Eric H. L. So acquired 100,000 shares of the firm’s stock in a transaction dated Tuesday, September 8th. The stock was bought at an average price of $12.39 per share, for a total transaction of $1,239,000.00. Following the completion of the acquisition, the insider owned 4,465,014 shares in the company, valued at approximately $55,321,523.46. The trade was a 2.29% increase in their position. Additional details regarding this purchase are available in the official SEC disclosure. In the last three months, insiders purchased 688,000 shares of company stock worth $8,422,830. 15.00% of the stock is owned by corporate insiders.

Institutional Trading of Cybin

An institutional investor recently bought a new position in Cybin stock. AXQ Capital LP purchased a new position in shares of Cybin Inc. (NASDAQ:HELP – Free Report) in the 2nd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm purchased 11,315 shares of the company’s stock, valued at approximately $75,000. Institutional investors and hedge funds own 17.94% of the company’s stock.

Cybin Company Profile

(Get Free Report)

Cybin Inc is a clinical-stage biotechnology company focused on developing psychedelic-based therapeutics for mental health conditions. The company combines psychedelic compounds with drug-delivery technologies and treatment protocols designed to improve the safety, consistency and duration of psychedelic-assisted therapies.

Cybin’s development programs have included CYB003, an investigational deuterated psilocybin therapy being studied for major depressive disorder, and CYB004, an investigational formulation of N,N-dimethyltryptamine (DMT) being evaluated for generalized anxiety disorder.

Further Reading